Completed PHASE2 INTERVENTIONAL NCT00199433

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease

Sponsor: Kyowa Kirin Co., Ltd.

Conditions Movement Disorder Syndrome Parkinson's Disease

Interventions Istradefylline (KW-6002)

Updated 7 times since 2017 Last updated: Apr 23, 2024 Started: May 31, 2005 Primary completion: Jul 31, 2006 Completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00199433, this PHASE2 trial focuses on Movement Disorder Syndrome and Parkinson's Disease and remains completed. Sponsored by Kyowa Kirin Co., Ltd., it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2024 — Jul 2024 [monthly]

Completed PHASE2
Oct 2021 — May 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyowa Kirin Co., Ltd.
Kyowa Kirin, Inc.

Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Princeton, United States